![John Furey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Furey
Director/Board Member at
VAXCYTE, INC.
Net worth: 272 728 $ as of 31/05/2026
Profile
John P.
Furey is Chief Executive Officer & Director at Imvax, Inc. since 2019.
Mr. Furey is Independent Director at Vaxcyte, Inc. starting in 2024.
Former roles include Independent Director at Sensorion SA from 2019 to 2025, Independent Non-Executive Director at Adaptimmune Therapeutics Plc from 2018 to 2025, Analyst at PanAgora Asset Management, Inc., Senior Vice President & Head-Global Operations at Baxalta, Inc. from 2015 to 2016, General Manager-Vaccine Business Unit at Huizhi Pharmaceutical (Dalian) Co., Ltd., and Chief Operating Officer at Spark Therapeutics, Inc. from 2016 to 2018.
Education includes undergraduate studies at Trinity College Dublin and an MBA from Saint Joseph's University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 15/06/2026 | 5,306 ( 0% ) | 272 728 $ | 31/05/2026 | |
| 11/04/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
John Furey active positions
| Companies | Position | Start |
|---|---|---|
| VAXCYTE, INC. | Director/Board Member | 02/07/2024 |
ImVax, Inc.
 ImVax, Inc. BiotechnologyHealth Technology Engages in research and development in biotechnology | Chief Executive Officer | 10/09/2019 |
Former positions of John Furey
| Companies | Position | End |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Director/Board Member | 14/11/2025 |
| SENSORION | Director/Board Member | 01/04/2025 |
| SPARK THERAPEUTICS, INC. | Chief Operating Officer | 31/12/2018 |
| BAXALTA INC | Corporate Officer/Principal | 01/06/2016 |
PanAgora Asset Management, Inc.
 PanAgora Asset Management, Inc. Investment ManagersFinance PanAgora seeks to deliver attractive, risk-adjusted returns on behalf of their clients. The firm utilizes broad investment capabilities across global regions, risk levels, and asset classes including risk efficient, multi alpha, absolute return and active equity strategies. Buy and sell decisions are based on the rigorous implementation of the models’ recommended allocations. Individual portfolios are adjusted for the client’s return objective, risk tolerance and investment guidelines. | Analyst-Equity | 31/12/2009 |
Training of John Furey
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
44
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
PanAgora Asset Management, Inc.
PanAgora Asset Management, Inc. Investment ManagersFinance PanAgora seeks to deliver attractive, risk-adjusted returns on behalf of their clients. The firm utilizes broad investment capabilities across global regions, risk levels, and asset classes including risk efficient, multi alpha, absolute return and active equity strategies. Buy and sell decisions are based on the rigorous implementation of the models’ recommended allocations. Individual portfolios are adjusted for the client’s return objective, risk tolerance and investment guidelines. | Finance |
Baxalta, Inc.
 Baxalta, Inc. Pharmaceuticals: MajorHealth Technology Engages in research, development and manufacture of therapies and biopharmaceutical products | Health Technology |
Trinity College Dublin
 Trinity College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pfizer Pharmaceuticals Ltd.
 Pfizer Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Health Technology |
Sensorion SA
 Sensorion SA Pharmaceuticals: MajorHealth Technology Operates as a research and development company that discovers drugs to treat inner ear disorders | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Develops therapy products for debilitating diseases | Health Technology |
Adaptimmune Therapeutics Plc
 Adaptimmune Therapeutics Plc BiotechnologyHealth Technology Manufactures vaccines and cancer immunotherapy products | Health Technology |
Vaxcyte, Inc.
 Vaxcyte, Inc. BiotechnologyHealth Technology Develops vaccines for infectious diseases | Health Technology |
ImVax, Inc.
ImVax, Inc. BiotechnologyHealth Technology Engages in research and development in biotechnology | Health Technology |
Saint Joseph's University
 Saint Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- John Furey
